Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea
    Petty, Amy J.
    Emge, Drew A.
    Blanchard, Sarah K.
    Selim, Maria Angelica
    Scoggins, Kim
    Liu, Beiyu
    Green, Cynthia L.
    Cardones, Adela R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 390 - 392
  • [32] Evaluation of efficacy and safety of Lascufloxacin tablet for Nursing and healthcareassociated pneumonia: Single-arm, open-label clinical trial
    Hosogaya, Naoki
    Takazono, Takahiro
    Ota, Kenji
    Ito, Yuta
    Ashizawa, Nobuyuki
    Takeda, Kazuaki
    Iwanaga, Naoki
    Yoshino, Yukari
    Ishikawa, Yasuyuki
    Izumikawa, Koichi
    Yatera, Kazuhiro
    Yanagihara, Katsunori
    Mukae, Hiroshi
    RESPIROLOGY, 2023, 28 : 204 - 205
  • [33] An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder
    Kaplan, Alicia
    Franzen, Michael D.
    Nickell, P. V.
    Ransom, Danielle
    Lebovitz, Paul J.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2014, 18 (01) : 11 - 15
  • [34] Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults
    Paradis, Erin M.
    Tikhonov, Oleg
    Cao, Xin
    Kharit, Susanna M.
    Fokin, Aleksandr
    Platt, Heather L.
    Banniettis, Natalie
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4177 - 4182
  • [35] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [36] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [37] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Bai, Yuxian
    Xu, Jianming
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
    Xu, Jianming
    Li, Jie
    Bai, Chunmei
    Xu, Nong
    Zhou, Zhiwei
    Li, Zhiping
    Zhou, Caicun
    Jia, Ru
    Lu, Ming
    Cheng, Yuejuan
    Mao, Chenyu
    Wang, Wei
    Cheng, Ke
    Su, Chunxia
    Hua, Ye
    Qi, Chuan
    Li, Jing
    Wang, Wei
    Li, Ke
    Sun, Qiaoling
    Ren, Yongxin
    Su, Weiguo
    CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3486 - 3494
  • [40] An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment
    Alexandru, Bogdana Ariana
    Rat, Lavinia Alina
    Moldovan, Andrada Florina
    Mihancea, Petru
    Maris, Lavinia
    MEDICINA-LITHUANIA, 2022, 58 (06):